192 related articles for article (PubMed ID: 23369941)
1. The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration.
Burger IA; Vargas HA; Donati OF; Andikyan V; Sala E; Gonen M; Goldman DA; Chi DS; Schöder H; Hricak H
Gynecol Oncol; 2013 Jun; 129(3):586-592. PubMed ID: 23369941
[TBL] [Abstract][Full Text] [Related]
2. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
Vargas HA; Burger IA; Goldman DA; Miccò M; Sosa RE; Weber W; Chi DS; Hricak H; Sala E
Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of the Sum of Metabolic Tumor Volume of Primary Tumor and Lymph Nodes Using 18F-FDG PET/CT in Patients With Cervical Cancer.
Hong JH; Min KJ; Lee JK; So KA; Jung US; Kim S; Eo JS
Medicine (Baltimore); 2016 Mar; 95(9):e2992. PubMed ID: 26945420
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging/positron emission tomography provides a roadmap for surgical planning and serves as a predictive biomarker in patients with recurrent gynecological cancers undergoing pelvic exenteration.
Vargas HA; Burger IA; Donati OF; Andikyan V; Lakhman Y; Goldman DA; Schöder H; Chi DS; Sala E; Hricak H
Int J Gynecol Cancer; 2013 Oct; 23(8):1512-9. PubMed ID: 24257566
[TBL] [Abstract][Full Text] [Related]
5. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.
Miccò M; Vargas HA; Burger IA; Kollmeier MA; Goldman DA; Park KJ; Abu-Rustum NR; Hricak H; Sala E
Eur J Radiol; 2014 Jul; 83(7):1169-1176. PubMed ID: 24767630
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of
Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
[TBL] [Abstract][Full Text] [Related]
7. Role of MR Imaging and FDG PET/CT in Selection and Follow-up of Patients Treated with Pelvic Exenteration for Gynecologic Malignancies.
Lakhman Y; Nougaret S; Miccò M; Scelzo C; Vargas HA; Sosa RE; Sutton EJ; Chi DS; Hricak H; Sala E
Radiographics; 2015; 35(4):1295-313. PubMed ID: 26172364
[TBL] [Abstract][Full Text] [Related]
8. Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma.
Satoh K; Patel D; Dieckmann W; Nilubol N; Kebebew E
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S714-20. PubMed ID: 26282908
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.
Im HJ; Oo S; Jung W; Jang JY; Kim SW; Cheon GJ; Kang KW; Chung JK; Kim EE; Lee DS
Medicine (Baltimore); 2016 May; 95(19):e3686. PubMed ID: 27175707
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration.
Husain A; Akhurst T; Larson S; Alektiar K; Barakat RR; Chi DS
Gynecol Oncol; 2007 Jul; 106(1):177-80. PubMed ID: 17477959
[TBL] [Abstract][Full Text] [Related]
13. Role of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenteration.
Donati OF; Lakhman Y; Sala E; Burger IA; Vargas HA; Goldman DA; Andikyan V; Park KJ; Chi DS; Hricak H
Eur Radiol; 2013 Oct; 23(10):2906-15. PubMed ID: 23652852
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters.
Chang S; Kim SJ
Cancer Biother Radiopharm; 2016 Feb; 31(1):1-6. PubMed ID: 26844846
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer.
Chung HH; Kang SY; Ha S; Kim JW; Park NH; Song YS; Cheon GJ
J Gynecol Oncol; 2016 Mar; 27(2):e15. PubMed ID: 26768781
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
18. Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.
Alongi P; Caobelli F; Gentile R; Stefano A; Russo G; Albano D; Baldari S; Gilardi MC; Midiri M
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):224-233. PubMed ID: 27565154
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of qualitative and quantitative ¹⁸F-FDG PET-CT parameters for predicting survival in recurrent carcinoma of the cervix.
Maharjan S; Sharma P; Patel CD; Sharma DN; Dhull VS; Jain SK; Thulkar S; Malhotra A; Kumar R
Nucl Med Commun; 2013 Aug; 34(8):741-8. PubMed ID: 23676840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
